ARTICLE

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia

Simon C Warby¹, Henk Visscher¹, Jennifer A Collins¹, Crystal N Doty¹, Catherine Carter¹, Stefanie L Butland¹, Anna R Hayden¹, Ichiro Kanazawa², Colin J Ross¹ and Michael R Hayden^{*,1}

Huntington disease (HD) results from CAG expansion in the huntingtin (*HTT*) gene. Although HD occurs worldwide, there are large geographic differences in its prevalence. The prevalence in populations derived from Europe is 10–100 times greater than in East Asia. The European general population chromosomes can be grouped into three major haplogroups (group of similar haplotypes): A, B and C. The majority of HD chromosomes in Europe are found on haplogroup A. However, in the East-Asian populations of China and Japan, we find the majority of HD chromosomes are associated with haplogroup C. The highest risk HD haplotypes (A1 and A2), are absent from the general and HD populations of China and Japan, and therefore provide an explanation for why HD prevalence is low in East Asia. Interestingly, both East-Asian and European populations share a similar low level of HD on haplogroup C. Our data are consistent with the hypothesis that different *HTT* haplotypes have different mutation rates, and geographic differences in *HTT* haplotypes explain the difference in HD prevalence. Further, the bias for expansion on haplogroup C in the East-Asian population cannot be explained by a higher average CAG size, as haplogroup C has a lower average CAG size in the general East-Asian population compared with other haplogroups. This finding suggests that CAG-tract size is not the only factor important for CAG instability. Instead, the expansion bias may be because of genetic *cis*-elements within the haplotype that influence CAG instability in *HTT*, possibly through different mutational mechanisms for the different haplogroups.

European Journal of Human Genetics (2011) 19, 561–566; doi:10.1038/ejhg.2010.229; published online 19 January 2011

Keywords: Huntington disease; prevalence; CAG expansion; CAG instability; haplotypes; Cis-elements

INTRODUCTION

Huntington disease (HD) is a progressive neurodegenerative disorder that is dominantly inherited and results from a mutation that expands the polymorphic trinucleotide (CAG) tract in *HTT*. The average CAG-tract size in the general population is 16–20 repeats. However, in HD patients the CAG-tract has expanded to 36 repeats or greater.¹

Although HD is found worldwide, there are significant geographic differences in its prevalence.^{2–5} The highest prevalence rates are reported for Western populations from Europe, where the minimum prevalence is >5 per 100 000 (Figure 1 and Supplementary Table 1). The origins of HD chromosomes in the United States, Canada, South Africa, Australia, the Caribbean, the Indian Subcontinent and Venezuela can be genealogically traced to European origins⁶ and have similar HD prevalence rates to Europe.

The origins of HD chromosomes in Eastern populations such as China and Japan are less clear. The minimum HD prevalence is estimated to be 0.1–0.5 per 100 000 in China^{7,8} and Japan.^{9–11} Previous studies have speculated that HD chromosomes in the Chinese population have the same origin as the European population.⁷ HD patients in China and Japan appear to have similar clinical and pathological features, but the disease occurs at a much lower frequency than in Europe.^{8,12} The reasons for the 10–100-fold lower prevalence

of HD in China and Japan (hereafter referred to as ‘East Asia’) compared with European populations is not well understood.

New mutations make a significant contribution to the prevalence of HD. Expanded CAG-tracts can be unstable and have a tendency to increase in size across generations, particularly when paternally transmitted.^{13,14} New mutations for HD occur when the CAG-tract of a transmitted chromosome expands to 36 repeats or greater. The intermediate allele (IA; 27–35 CAG) class of chromosomes have a larger than normal CAG-tract in *HTT*. Individuals with an IA will not develop HD themselves, but their offspring may be at risk of inheriting a CAG-tract that has expanded into the HD range (>35 CAG).¹⁵ Estimates of the mutation flow of the CAG-tract¹⁶ and the frequency of HD cases that do not have a previous family history of HD¹⁷ suggest the new mutation rate may be as high as 10% in some populations.

Furthermore, there is an inverse relationship between the CAG-tract size and the age of onset of the disease that accounts for the ‘anticipation’ of the disease (earlier onset) in subsequent generations.^{18,19} As the CAG-tract continues to expand from generation-to-generation, the age of onset gets earlier. Eventually, with large CAG-tract sizes (>60 repeats), the onset of the disease occurs before reproductive age (juvenile onset), and the disease chromosome does not have an opportunity to be passed on to the next generation.

¹Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada; ²Department of Clinical Neurology and Neuroscience, Faculty of Medicine, University of Tokyo, Tokyo, Japan

*Correspondence: Dr MR Hayden, Centre For Molecular Medicine & Therapeutics, BC Children's and Women's Hospital, 980 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada. Tel: +(604) 875 3535; Fax: +(604) 875 3819; E-mail: mrh@cmmmt.ubc.ca

Received 25 August 2010; revised 24 November 2010; accepted 25 November 2010; published online 19 January 2011

Figure 1 Worldwide estimates of the prevalence of HD. Overall, the prevalence of HD is much higher in European populations than in East Asia. Average minimum prevalence on the basis of several studies are shown (references in Supplementary Table 1). Note that prevalence studies occurring before the discovery of the HD gene in 1993 could underestimate the true prevalence of HD by as much as 14–24%.^{17,45} In particular, many of the studies in Africa have small sample sizes and the HD diagnosis has not confirmed by molecular testing. As HD phenocopy disorders are relatively common in Africa,⁴⁶ these studies could have significantly overestimated the HD prevalence in these regions. Currently, the Maracaibo region of Venezuela has the highest reported worldwide prevalence of HD (700 per 100 000).³⁹ Venezuela was colonized by the Spanish in the 16th century, and the origins of HD in Venezuela can be traced back to Europe.³⁸ Also see Harper,⁴ Conneally⁴⁷ and Al Jader *et al*² for earlier reviews on the worldwide prevalence of HD.

The current prevalence of HD in any population is therefore the result of the balance between the incidence of new mutations caused by CAG expansion into the disease range and the incidence of CAG expanded chromosomes eliminated by anticipation.²⁰

CAG expansion in European populations does not occur randomly, but is associated with specific *HTT* haplotypes. In a previous study, three broadly defined haplogroups (A, B and C) were found in the *HTT* region in the general population, but both HD chromosomes and intermediate alleles for HD were almost exclusively found on haplogroup A.²¹ Further, CAG-expanded chromosomes were significantly more likely to be associated with two specific haplogroup A variants (A1 and A2) than any other *HTT* haplotype. However, these variants (A1 and A2) were not exclusive to CAG-expanded chromosomes, suggesting that these variants might have an increased mutation rate relative to other *HTT* haplotypes in the general population. We have previously proposed that this increased association of CAG expansion with A1 and A2 in the European population is most consistent with the hypothesis that genetic *cis*-elements found on these haplotypes are predisposed to CAG expansion.^{21,22} The purpose of this study was to determine if HD chromosomes in populations of East-Asian descent arise on the same haplotype as seen in European populations.

METHODS

In order to determine the haplotypes of HD chromosomes in European ($n=199$ independent chromosomes from unrelated individuals >35 CAG, including 65 samples reported previously²¹) and Chinese and Japanese^{10,23} ($n=31$ independent unrelated chromosomes >35 CAG) populations, genotyping was performed at 21 tagSNP positions in the *HTT* region using a customised GoldenGate assay on the Illumina BeadArray platform. Phasing was performed using PHASE-2²⁴ with family trio information to assign the SNP alleles to chromosomes of known CAG size. CAG-tract size was measured using methods described previously.²⁵ Haplogroups were called using the criteria developed previously²¹ (Supplementary Table 2). Statistical analysis was performed using Excel or 'R' software (www.r-project.org) as appropriate. *P*-values are reported and indicated with nonsignificant (n.s.) when they exceed $\alpha=0.05$. Ethnicity of subjects was self-reported and confirmed by

independent self-reports of family members. The use of both previously collected de-identified archived samples and those collected from consenting UBC HD Clinic patients and families was approved for this study by the UBC/Children's and Women's Health Centre of British Columbia Research Ethics Board (UBC C&W REB H05-70532).

RESULTS AND DISCUSSION

Confirming our previous results, HD chromosomes in European populations are most likely to occur on a subset of *HTT*-specific haplotypes within haplogroup A (Supplementary Table 3).²¹ Variants A1 and A2 have the highest risk for CAG expansion in European populations (Odds Ratio 13.9 and 2.8; *P*-value 4.8×10^{-36} and 9.9×10^{-7} , respectively). CAG expansion may still occur on variant A3 (OR 0.9; *P*-value 0.82 n.s.) but in contrast, variants A4 and A5 (OR 0.2 and 0.0; *P*-value 6.6×10^{-4} and 2.9×10^{-4}) appear to be protected from the mutation relative to other haplotypes in European populations.

In contrast, HD chromosomes in East Asia were associated with different haplotypes than seen in Europe. In Chinese and Japanese, CAG expansion was most frequently associated with haplogroup C (OR 5.2; *P*-value 4.4×10^{-4}) and less commonly associated with A5 and haplogroup B (OR 0.4 and 0.5, *P*-value=0.11 n.s. and *P*-value=0.37 n.s.; Figure 2). We did not find any Chinese or Japanese chromosomes with CAG expansion on haplogroup variants A1 or A2, which was most common in Europe.

To determine the frequency of the different haplogroups on control chromosomes (<26 CAG), genotyping and phasing was performed on DNA from family trios in the general population from Europe ($n=428$ trios), China and Japan ($n=73$ trios). Haplogroup frequencies among control chromosomes in the general population were similar within the different European populations and within the East-Asian populations. (Supplementary Table 3). However, the *HTT* haplogroup frequencies in the general population (<26 CAG) are very different between the European and East-Asian populations (Figure 3). The A1 and A2 variants, highly associated with European CAG expanded chromosomes, were found in up to 20% of the general population

Figure 2 *HTT* haplogroups of CAG-expanded chromosomes (>35CAG). The HD mutation occurs on different haplogroups in East-Asian and European populations. In Europe, CAG expansion is most likely to be found on haplogroup A, particularly variants A1 and A2. In East Asia, CAG expansion is associated with different haplogroups, including haplogroup C. Note that 'Other' haplotypes (white) could not be easily categorized into haplogroup A, B or C. 'A-Other' haplogroup variants (grey) could not be easily categorized into a variant of haplogroup A. Number of chromosomes are indicated in brackets. The data are also presented in Supplementary Table 3.

Figure 3 *HTT* haplogroups of the general population (<27CAG). There is a diversity of haplogroups found in the general population of Europe, despite the fact that CAG expansion is most likely to occur on haplogroup A in this population (compare with Figure 2). Note that haplogroup A, and the variants with the highest risk of CAG expansion in the European population (A1 and A2, in red) are absent from the general population of China and Japan. Number of chromosomes are indicated in brackets. The data are also presented in Supplementary Table 3.

in Europe. In contrast, these two highest risk haplogroup variants are completely absent from the general population in East Asia in our sample. One explanation for the lower prevalence of HD in East Asia could therefore be the absence of predisposing A1 and A2 haplotypes in their general population.

Overall, the average CAG-tract size in the East-Asian general population was 16.9 repeats (Table 1). This is lower than the average CAG-tract size of 17.8 repeats in Europeans and consistent with previous reports.²⁶ In East Asia, the frequency of haplogroup C on HD chromosomes is significantly increased relative to the frequency of

Table 1 *HTT* haplotype frequency in East Asia and Europe (number of chromosomes are indicated in brackets)

	General population		HD chromosomes	
	East Asia	Europe	East Asia	Europe
Avg CAG	16.9	17.8	45.1	45.0
N	73	428	31	199
A-1	0.00	0.07 (29)	0.00	0.50 (100)
A-2	0.00	0.13 (54)	0.00	0.29 (57)
A-3	0.03 (02)	0.12 (50)	0.00	0.11 (22)
A-4	0.11 (08)	0.09 (37)	0.00	0.02 (03)
A-5	0.27 (20)	0.06 (27)	0.13 (04)	0.00
A-Other	0.00	0.01 (05)	0.00	0.02 (05)
B	0.16 (12)	0.04 (19)	0.10 (03)	0.00
C	0.40 (29)	0.47 (200)	0.77 (24)	0.02 (05)
Other	0.03 (02)	0.02 (07)	0.00	0.04 (07)

haplogroup C in the general population (Supplementary Table 4, χ^2 *P*-value 4.4×10^{-4}). This suggests that new mutations for HD do not occur randomly on any chromosome, but that there is a mutation bias that increases the probability of CAG-tract expansion on haplogroup C in this population.

Interestingly, HD occurs on haplogroup C at a similar frequency in both Europe and East-Asian populations, and may be the result of a baseline level of CAG instability of this specific haplogroup. HD prevalence in Europe on average is estimated at 7.5 in 100 000 and expansion occurs on haplogroup C only 2% of the time in this population. Therefore, the specific prevalence of HD on haplogroup C in Europe would be estimated at 0.15 in 100 000. Although the overall prevalence of HD in East Asia is 10–100 times lower than in Europe, this is similar to the estimated specific prevalence of HD on haplogroup C in the East of 0.19 per 100 000 (Table 2). Although the frequency of HD on haplogroup C in Europe is only a minor proportion of the overall prevalence, the specific prevalence of HD on haplogroup C is very similar to that in East Asia. Haplogroup C remains the most susceptible haplogroup in East Asia because the haplogroup variants with higher risk (A1 and A2) are absent from this population.

The overall prevalence of HD in any population is the balance between the incidence of new mutations for HD and loss of HD chromosomes because of negative selection of very large CAG-tracts that result in juvenile onset HD. This equilibrium is therefore critically dependant on forces that alter the CAG-tract size of normal (<27 CAG) and intermediate alleles (27–35 CAG) of *HTT*, which are not subject to significant negative selection. Why is the HD mutation more likely to occur on specific *HTT* haplotypes? We propose two potentially complementary explanations:^{21,22,27}

- (1) The bias is due to a larger average CAG-tract size of that haplogroup in the general population. The larger average CAG size could be due to a founder mutation or genetic drift. CAG instability is positively and exponentially related the size of the CAG-tract,^{16,28} and a larger average CAG-tract size would make that haplogroup more likely to expand and become a new mutation for HD.
- (2) Certain haplogroups contain genetic *cis*-elements in the *HTT* region that increase the probability of CAG expansion relative to other haplogroups. These *cis*-elements may be particularly important when the CAG-tract size is in the normal or intermediate range and the influence of CAG-tract size itself is reduced.

Table 2 Prevalence of CAG-expansion on haplogroup C

	Avg overall HD prevalence per 100 000	Fraction of total		Prevalence of HD on haplogroup C
		Haplogroup		
Europe	7.5	C	0.02	0.15
		All non-C	0.98	
East Asia	0.25	C	0.77	0.19
		All non-C	0.23	

Abbreviation: HD, Huntington disease.

The prevalence of HD on haplogroup C is similar between East Asia and Europe. HD is far more prevalent in Europe (7.5/100 000), but a small fraction of the total number of CAG-expanded chromosomes occur on haplogroup C (2%). Despite the lower overall prevalence of HD, the prevalence of CAG expansion specifically on haplogroup C is similar in the East Asian populations.

To discriminate between these two possibilities, we compared the CAG-tract size distribution between C and non-C haplotypes in East Asia (Figure 4). Interestingly, the mean CAG-tract size of haplogroup-C chromosomes (16.0 repeats) was not higher than non-C chromosomes (17.2 repeats) in the general population of East Asia. This is not consistent with the first explanation above because the CAG expanded chromosomes on haplogroup C do not appear to have come from a pool of intermediate alleles on the same haplotype in East Asia.

Instead, the data argue that CAG-tract size cannot be the only factor important for CAG instability and supports the second explanation above. This conclusion is further supported by a clear precedent for genetic *cis*-elements influencing CAG instability for other genes.²⁹ Although there are many CAG-tract-containing genes in the genome, each has a different propensity to CAG instability that is not explained by differences in mean CAG-tract size³⁰ but could be explained by *cis*-elements that influence CAG instability. For example, CTCF binding sites located *cis* to the *ATXN7* gene can regulate CAG hyperinstability at that locus.^{31,32} We hypothesize that genetic *cis*-elements present in different *HTT* haplogroups may be regulating CAG instability at the *HTT* locus. Further experiments are clearly needed to demonstrate this.

Although the sample size is relatively small, particularly in the East-Asian samples, our data are consistent with the hypothesis that different *HTT* haplotypes have different mutation rates, and geographic differences in *HTT* haplotypes explain the difference in prevalence of HD (Figure 5a). The A1 and A2 haplotypes that comprise the majority of European HD chromosomes are not present in the East-Asian populations, and may have arisen in Europe following the separation of these two populations (Figure 5b) about 25 000 years ago.^{33,34} There also appears to be a consistent trend of higher prevalence estimates in Western Europe compared with Eastern Europe, suggesting the A1 and A2 haplotypes may have originated from the Western coast of Europe. This prevalence trend is emphasised in Finland³⁵ (0.5 per 100 000), where geographic isolation and reduced immigration is believed to result in a lower prevalence of HD than its coastal neighbours Sweden³⁶ (5 per 100 000) and Norway³⁷ (7 per 100 000). The genealogical path of HD into many European-derived populations in North America and Australia is known,⁶ although there is a notable lack of basic prevalence information from South America, aside from Venezuela.^{38,39} Prevalence estimates from the Indian subcontinent are also limited to one study of immigrants to the UK,⁴⁰ but these data suggest the prevalence of HD in India may be higher than in East Asia. This is supported by further molecular analysis of *HTT* in the Indian population⁴¹ but warrants further examination. More data are also needed from Africa, where a number of studies have found that the prevalence of HD is

Figure 4 CAG size distributions of haplogroup C (a) East Asia and (b) Europe. In East Asia, the majority of HD mutations occur on haplogroup C. In the general population of East Asia, the average CAG-tract size of haplogroup C is less than other haplogroups, suggesting that the bias of expansion is not simply because of a large average CAG-tract size (Note that the CAG-tract size distribution is discontinuous because of the fact that there is an ascertainment bias towards discovering chromosomes with >36CAG due to HD symptoms).

Figure 5 Model of CAG expansion in *HTT*. (a) At least two mutation rates and potentially two mutational mechanisms, may contribute to CAG expansion in *HTT*. The low prevalence of HD on haplogroup C is consistent in both East-Asian and European populations and is explained by a low level of CAG expansion that occurs on haplogroup C (blue). The mutation rate of the second mechanism (red) is much higher and therefore results in a higher overall prevalence of HD in European populations. (b) The genetic changes that produced haplotypes A1/A2 appear to have occurred after the separation of Asian and European chromosomes (red arrows), as these haplotypes are completely absent from the Chinese and Japanese populations. The genetic changes that produced A1/A2 may have altered *cis*-elements in and around the *HTT* gene, resulting in a higher rate of CAG-expansion. Chromosomes from Europe serve as the origin of HD in several other populations including North and South America, South Africa and Australia through human migration.⁶

much higher in Whites than Blacks,^{42,43} presumably because of the introduction of HD in South Africa and Mauritius from Europe.^{6,44}

Despite the similarities in clinical phenotype,^{8,26} the origin of the majority of HD chromosomes in East Asia and Europe are different. The prevalence of HD is 10–100-fold greater in Europe than in East Asia, and the haplogroups that are closely associated with CAG expansion in European populations (haplogroups A1 and A2), are found in up to 47% of a sample of the general population in Europe.²¹ In contrast, these haplogroups are absent from populations of Chinese or Japanese descent, and provide an explanation for why the HD prevalence is low in East-Asian populations. However, there may be a common origin of a subset of HD cases found on haplogroup C, as the

prevalence of HD was similar, although at a low level in both populations. Overall, we find that CAG expansion at the *HTT* locus occurs preferentially on specific haplogroups. The highest risk haplogroups are found in the European population, which presumably emerged after the separation of European and Asian populations.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The authors thank the HD families for the generous use of their DNA for these studies. Funding has been provided by the Canadian Genetic Diseases Network

(CGDN), Huntington Society of Canada (HSC), Michael Smith Foundation for Health Research (MSFHR), Canadian Institutes of Health Research (CIHR), Child and Family Research Institute (CFRI) and the Huntington Disease Society of America (HDSA)/High Q Foundation.

- 1 Walker FO: Huntington's disease. *Lancet* 2007; **369**: 218–228.
- 2 Al-Jader LN, Harper PS, Krawczak M, Palmer SR: The frequency of inherited disorders database: prevalence of Huntington disease. *Community Genet* 2001; **4**: 148–157.
- 3 Andrew SE, Hayden MR: Origins and evolution of Huntington disease chromosomes. *Neurodegeneration* 1995; **4**: 239–244.
- 4 Harper PS: The epidemiology of Huntington's disease. *Hum Genet* 1992; **89**: 365–376.
- 5 Squitieri F, Andrew SE, Goldberg YP *et al*: DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. *Hum Mol Genet* 1994; **3**: 2103–2114.
- 6 Hayden MR: *Huntington's Chorea*. New York: Springer, 1981.
- 7 Leung CM, Chan YW, Chang CM, Yu YL, Chen CN: Huntington's disease in Chinese: a hypothesis of its origin. *J Neurol Neurosurg Psychiatry* 1992; **55**: 681–684.
- 8 Chang CM, Yu YL, Fong KY *et al*: Huntington's disease in Hong Kong Chinese: epidemiology and clinical picture. *Clin Exp Neurol* 1994; **31**: 43–51.
- 9 Nakashima K, Watanabe Y, Kusumi M *et al*: Epidemiological and genetic studies of Huntington's disease in the San-in area of Japan. *Neuroepidemiology* 1996; **15**: 126–131.
- 10 Masuda N, Goto J, Murayama N, Watanabe M, Kondo I, Kanazawa I: Analysis of triplet repeats in the huntingtin gene in Japanese families affected with Huntington's disease. *J Med Genet* 1995; **32**: 701–705.
- 11 Adachi Y, Nakashima K: Population genetic study of Huntington's disease—prevalence and founder's effect in the San-in area, western Japan. *Nippon Rinsho* 1999; **57**: 900–904.
- 12 Narabayashi H: Huntington's Chorea in Japan: review of the literature. *Adv Neurol* 1973; **1**: 253–259.
- 13 De Rooij KE, Koning Gans PA, Skraastad MI *et al*: Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range. *J Med Genet* 1993; **30**: 996–1002.
- 14 Goldberg YP, McMurray CT, Zeisler J *et al*: Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. *Hum Mol Genet* 1995; **4**: 1911–1918.
- 15 Semaka A, Creighton S, Warby S, Hayden MR: Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. *Clin Genet* 2006; **70**: 283–294.
- 16 Falush D, Almqvist EW, Brinkmann RR, Iwasa Y, Hayden MR: Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. *Am J Hum Genet* 2001; **68**: 373–385.
- 17 Almqvist EW, Elterman DS, MacLeod PM, Hayden MR: High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. *Clin Genet* 2001; **60**: 198–205.
- 18 Langbehn DR, Hayden MR, Paulsen JS: CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**: 397–408.
- 19 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR: A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. *Clin Genet* 2004; **65**: 267–277.
- 20 Rubinstein DC, Amos W, Leggo J *et al*: Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. *Nat Genet* 1994; **7**: 525–530.
- 21 Warby SC, Montpetit A, Hayden AR *et al*: CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. *Am J Hum Genet* 2009; **84**: 351–366.
- 22 Warby SC, Visscher H, Butland S, Pearson CE, Hayden MR: Response to Falush: a role for cis-element polymorphisms in HD. *Am J Hum Genet* 2009; **85**: 942–945.
- 23 Almqvist E, Spence N, Nichol K *et al*: Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. *Hum Mol Genet* 1995; **4**: 207–214.
- 24 Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 2001; **68**: 978–989.
- 25 Potter NT, Spector EB, Prior TW: Technical standards and guidelines for Huntington disease testing. *Genet Med* 2004; **6**: 61–65.
- 26 Soong BW, Wang JT: A study on Huntington's disease associated trinucleotide repeat within the Chinese population. *Proc Natl Sci Counc Repub China B* 1995; **19**: 137–142.
- 27 Falush D: Haplotype background, repeat length evolution, and Huntington's disease. *Am J Hum Genet* 2009; **85**: 939–942.
- 28 Kremer B, Almqvist E, Theilmann J *et al*: Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. *Am J Hum Genet* 1995; **57**: 343–350.
- 29 Pearson CE, Edamura KN, Cleary JD: Repeat instability: mechanisms of dynamic mutations. *Nat Rev Genet* 2005; **6**: 729–742.
- 30 Butland SL, Devon RS, Huang Y *et al*: CAG-encoded polyglutamine length polymorphism in the human genome. *BMC Genomics* 2007; **8**: 126.
- 31 Libby RT, Monckton DG, Fu YH *et al*: Genomic context drives SCA7 CAG repeat instability, while expressed SCA7 cDNAs are intergenerationally and somatically stable in transgenic mice. *Hum Mol Genet* 2003; **12**: 41–50.
- 32 Libby RT, Hagerman KA, Pineda VV *et al*: CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. *PLoS Genet* 2008; **4**: e1000257.
- 33 Gutenkunst RN, Hernandez RD, Williamson SH, Bustamante CD: Inferring the joint demographic history of multiple populations from multidimensional SNP frequency data. *PLoS Genetics* 2009; **5**: e1000695–e1000695.
- 34 Garrigan D, Kingan SB, Pilkington MM *et al*: Inferring human population sizes, divergence times and rates of gene flow from mitochondrial, X and Y chromosome resequencing data. *Genetics* 2007; **177**: 2195–2207.
- 35 Palo J, Somer H, Ikonen E, Karila L, Peltonen L: Low prevalence of Huntington's disease in Finland. *Lancet* 1987; **2**: 805–806.
- 36 Mattsson B: Huntington's chorea in Sweden. *Acta Psychiatrica Scandinavica Supplementum* 1974; **255**: 211–220.
- 37 Saugstad L, Odegård O: Huntington's chorea in Norway. *Psychol Med* 1986; **16**: 39–48.
- 38 Paradisi I, Hernández A, Arias S: Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation. *J Hum Genet* 2008; **53**: 127–135.
- 39 Avila-Giron R: Medical and social aspects of Huntington's chorea in the state of Zulia, Venezuela. *Adv Neurol* 1973; **1**: 261–266.
- 40 Shiwach RS, Lindenbaum RH: Prevalence of Huntington's disease among UK immigrants from the Indian subcontinent. *Br J Psychiatry: J Mental Sci* 1990; **157**: 598–599.
- 41 Saleem Q, Roy S, Murgood U *et al*: Molecular analysis of Huntington's disease and linked polymorphisms in the Indian population. *Acta Neurol Scand* 2003; **108**: 281–286.
- 42 Hayden MR, Beighton P: Huntington's chorea in the Cape coloured community of South Africa. *S Afr Med J* 1977; **52**: 886–888.
- 43 Hayden MR, MacGregor JM, Beighton PH: The prevalence of Huntington's chorea in South Africa. *S Afr Med J* 1980; **58**: 193–196.
- 44 Scholefield J, Greenberg J: A common SNP haplotype provides molecular proof of a founder effect of Huntington disease linking two South African populations. *Eur J Hum Genet* 2007; **15**: 590–595.
- 45 Siesling S, Vetger-van de Vliet M, Losekoot M *et al*: Family history and DNA analysis in patients with suspected Huntington's disease. *J Neurol Neurosurg Psychiatry* 2000; **69**: 54–59.
- 46 Margolis RL, Rudnicki DD, Holmes SE: Huntington's disease like-2: review and update. *Acta Neurol Taiwan* 2005; **14**: 1–8.
- 47 Conneally PM: Huntington disease: genetics and epidemiology. *Am J Hum Genet* 1984; **36**: 506–526.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)